Bipolar Disorders: Mixed States, Rapid-Cycling, and Atypical Forms

107 Bipolar I and bipolar II: a dichotomy?Tohen, M., Hennen, J., Zarate, C. M., et al. (2000). Two-year syndromal and functional recoveryin 219 cases of first-episode major affective disorder with psychotic features. Am. J. Psychiatry,157, 220–8.Tondo, L., Jamison, K., and Baldessarini, R. J. (1997). Antisuicide effects of lithium. Ann. N. Y.Acad. Sci., 836, 339–51.Tondo, L., Baldessarini, R. J., Hennen, J., and Floris, G. (1998). Lithium maintenancetreatment of depression and mania in bipolar I and bipolar II disorders. Am. J. Psychiatry,155, 638–45.Tondo, L., Baldessarini, R. J., and Floris, G. (2001). Long-term clinical effectiveness of lithiummaintenance treatment in types I and II bipolar disorders. Br. J. Psychiatry, 178 (suppl. 41),184–90.Tsuang, M. T., Woolson, R., and Fleming, J. A. (1979). Long-term outcome of major psychoses:schizophrenia and affective disorders compared with psychiatrically symptom-free surgicalconditions. Arch. Gen. Psychiatry, 36, 1295–301.Vieta, E. (1999). Diagnosis and classification of psychiatric disorders. In Anticonvulsants inPsychiatry, ed. N. Sussman, pp. 3–8. Round table series 64. London: Royal Society of MedicinePress.Vieta, E., (2003). Atypical antipsychotics in the treatment of mood disorders. Curr. Opin.Psychiatry, 16, 23–7.Vieta, E., Gastó, C., Otero, A., et al. (1994). Características clínicas del trastorno bipolar tipo II,una categoría válida de difícil diagnóstico. Psiquiatr. Biol., 1, 104–10.Vieta, E., Gastó, C., Otero, A., Nieto, E., and Vallejo, J. (1997a). Differential features betweenbipolar I and bipolar II disorder. Compr. Psychiatry, 38, 98–101.Vieta, E., Benabarre, A., Colom, F., et al. (1997b). Suicidal behavior in bipolar I and bipolar IIdisorder. J. Nerv. Ment. Dis., 185, 407–9.Vieta, E., Colom, F., Martínez-Arán, A., Benabarre, A., and Gastó, C. (1999). Personalitydisorders in bipolar II patients. J. Nerv. Ment. Dis., 187, 245–8.Vieta, E., Colom, F., Martínez-Arán, A., et al. (2000). Bipolar II disorder and comorbidity.Comp. Psychiatry, 41, 339–43.Vieta, E., Gastó, C., Colom, F., et al. (2001a). The role of risperidone in bipolar II: an open sixmonthstudy. J. Affect. Disord., 67. 213–19.Vieta, E., Goikolea, J. M., Corbella, B., et al. (2001b). Risperidone safety and efficacy in thetreatment of bipolar and schizoaffective disorders: results from a six-month, multicenter,open study. J. Clin. Psychiatry, 62, 818–25.Vieta, E., Reinares, M., Corbella, B., et al. (2001c). Olanzapine as long-term adjunctive therapyin treatment-resistant bipolar disorder. J. Clin. Psychopharmacol., 21, 469–73.Vieta, E., Colom, F., and Martínez-Arán, A. (2002a). Chronicity, milder forms and cognitiveimpairment in bipolar disorder. In Bipolar Disorder, ed. M. Maj, H. S. Akiskal, J. J. López-Ibor,and N. Sartorius, pp. 182–4. New York: John Wiley.Vieta, E., Torrent, C., García-Ribas, G., et al. (2002b). Use of topiramate in treatment-resistantbipolar-spectrum disorders. J. Clin. Psychopharmacol., 22, 431–5.Vieta, E., Parramon, G., Padrell, E., et al. (2002c). Quetiapine in the treatment of rapid cyclingbipolar disorder. Bipolar Disord., 4, 335–40.